Join MySLAS Social

LEARN MORE AT SLAS2018

Growing Impact of Biologics in Drug Discovery and Therapeutics

“Biologics make up an estimated 25 to 30 percent of therapeutic agents on the market today. This demand for therapeutic biologics has exceeded what can be provided by traditional manual laboratory methods and has opened the door for the development of automation and miniaturization to accelerate the discovery process and offer new therapeutic opportunities,” says Daniel Sipes, M.S., director of automation at Genomics Institute, Novartis Research Foundation, (San Diego, CA).

LOOKING BACK ON THE YEAR

Center Yourself: 2017 SLAS Annual Report

At the center of today’s many changes, challenges and choices are SLAS members, the principal stakeholders in the unique and united community of professionals who thrive at the intersection of applied and basic life sciences discovery and technology. Relevant, collaborative and future-focused describe SLAS in 2017. To the benefit of more than 18,000 members worldwide, significant strides forward were made to enhance SLAS operations and the Society’s resource-rich menu of programs, products, services and events. 

DRUG DISCOVERY AND COMMERCIALIZATION

Cathy Tralau-Stewart: Creating the Secret Sauce for Translational Science

With 25-plus years of drug discovery experience spanning both industry and academia, Cathy Tralau-Stewart could write a book about the meticulous work required for a drug compound to progress through the pipeline. In her role at UCSF’s Catalyst Program, she unites various collaborators to keep breakthrough science in motion.

SLAS COVER AUTHOR SPOTLIGHT

Eun Jeong Cho

College of Pharmacy
The University of Texas at Austin

Weian Zhao, Ph.D.

Associate Professor
University of California, Irvine